Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Warfarin dosing and cytochrome P450 2C9 polymorphisms.

Thrombosis and haemostasis - 1 Jun 2004

Joffe Hylton V, Xu Ruliang, Johnson F Bradley, Longtine Janina, Kucher Nils, Goldhaber Samuel Z

Abstract excerpt

Two cytochrome P450 2C9 (CYP2C9) polymorphisms, CYP2C9*2 and *3, metabolize warfarin inefficiently. We assessed the extent to which these polymorphisms explain very low warfarin dose requirements and hemorrhagic complications after excluding non-genetic determinants of warfarin dosing. In this retrospective observational study, 73 patients with stable warfarin doses for > or =1 month and International Normalized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Hemorrhage

Share to Pharmacogenetics

Share to Predictive Value of Tests

Share to Regression Analysis

Share to Warfarin

Source

Identifiers

PMID: 15175798
DOI: 10.1160/TH04-02-0083

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Warfarin dosing and cytochrome P450 2C9 polymorphisms.PMID 15175798Read ↗

Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.Semantic proximity Read ↗

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.Semantic proximity Read ↗

Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients.Semantic proximity Read ↗

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.Semantic proximity Read ↗

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.Semantic proximity Read ↗

Warfarin pharmacogenomics.Semantic proximity Read ↗

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.Semantic proximity Read ↗

First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.Semantic proximity Read ↗

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Semantic proximity Read ↗

CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic DosingSemantic proximity Read ↗

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype.Semantic proximity Read ↗

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.